共查询到20条相似文献,搜索用时 78 毫秒
1.
胃癌是最为常见的恶性肿瘤之一,在中国其发病率和死亡率均较高,大多数胃癌初诊即已为晚期,预后较差,目前治疗现状仍不理想。免疫逃逸是肿瘤发生发展的一主要机制,细胞程序性死亡受体-1(programmed death-1,PD-1)及细胞程序性死亡配体(programmed death-ligand 1,PD-L1)是导致免疫逃逸的重要分子,PD-1与PD-L1结合是肿瘤细胞免疫逃逸的重要发病机制之一,特异性阻断二者结合,可达到杀灭肿瘤细胞的目的。PD-1/PD-L1抑制剂可明显改善晚期胃癌患者预后,并且PD-1/PD-L1抑制剂联合化疗、靶向治疗、放疗等可进一步提高疗效。本文就PD-1/PD-L1抑制剂联合治疗在晚期胃癌中的治疗进展进行综述。 相似文献
3.
胃癌是世界发病率最高的恶性肿瘤之一,其发病率和死亡率均较高。随着医疗技术的突飞猛进,免疫治疗成为胃癌的一项新策略。但是并非所有胃癌患者都能从单一的免疫治疗中获益。目前的治疗策略主要包括免疫联合其他治疗方式以及选择合适的生物标志物用于筛选优势群体等策略。本文就近年来免疫检查点抑制剂在晚期胃癌各线治疗中的最新研究和应用、免疫联合其他方式治疗胃癌和预测疗效的生物标志物的进展展开综述,为胃癌的临床治疗提供参考。 相似文献
4.
5.
结直肠癌是常见的消化道恶性肿瘤.免疫检查点抑制剂在肿瘤免疫逃逸中发挥着至关重要的作用,成为抗肿瘤免疫治疗的热点.免疫检查点抑制剂在多种实体瘤的治疗中取得了令人瞩目的效果.在结直肠癌的治疗领域,尤其是针对微卫星不稳定(MSI)和(或)错配修复缺陷(dMMR)的结直肠癌患者,检查点抑制剂亦显示出了良好的疗效及安全性.本文概... 相似文献
6.
7.
8.
黄昱 《中国肿瘤临床与康复》2023,(6):340-344
乳腺癌是全球女性中最常见的恶性肿瘤,虽然多数乳腺癌患者确诊时为早期且可被治愈,但仍有部分患者为复发或转移性乳腺癌,需要进一步提高治疗疗效,改善预后。近年来,免疫检查点抑制剂(ICI)在乳腺癌中也有越来越多的探索,并成为乳腺癌重要的治疗药物之一。由于不同分子亚型乳腺癌的肿瘤微环境存在异质性,对ICI的反应也不一致。文章对ICI治疗不同分子亚型乳腺癌的研究进展进行了综述。 相似文献
9.
周洁吴强许峰代爽张红娥 《临床肿瘤学杂志》2021,26(7):649-656
小细胞肺癌(SCLC)属于高度恶性神经内分泌癌,早期即易发生转移,确诊时60%~70%已处于广泛期,手术治疗机会小.虽然SCLC起始对含铂方案系统化疗±放疗的一线治疗高度敏感,但多数在一线治疗后短期内即出现复发与转移.尽管近30年来对SCLC治疗不断探索与研究,仍缺乏有效治疗手段,患者长期生存率极低.近年来以免疫检查点... 相似文献
11.
近年来许多研究证实免疫检查点抑制剂在多种癌症治疗中的潜力。自然杀伤细胞(natural killer cell,NK)是固有免疫系统的重要组成部分,在肿瘤免疫监视中发挥重要作用。其作用效应依赖于其与抑制和(或)激动受体的结合,无需主要组织相容性复合体(major histocompatibility complex,MHC)便能有效杀伤肿瘤。NK细胞对实体和血液肿瘤有巨大的杀伤潜力,已被越来越多的研究证实是肿瘤免疫治疗的理想靶点。NK细胞上一些新发现的免疫检查点受体被证实在肿瘤微环境中介导NK细胞的功能障碍,是理想的肿瘤免疫治疗靶点。本文将重点论述近年来新发现的免疫检查点受体在调节NK细胞功能中的作用及其在肿瘤免疫治疗中的潜在应用。 相似文献
12.
13.
免疫检查点对于维持自身免疫耐受、避免免疫系统对正常组织进行攻击发挥着至关重要的作用。肿瘤细胞能够利用免疫检查点通路的激活逃避免疫系统的识别。目前最重要的免疫检查点为细胞毒T淋巴细胞相关抗原-4(CTLA-4)、程序性死亡受体-1(PD-1)及程序性死亡受体配体-1(PD-L1)。肿瘤细胞PD-L1通过与活化的T细胞的PD-1结合,能够通过诱导T细胞的凋亡降低肿瘤免疫反应。免疫检查点抑制剂的应用能够延长肿瘤患者的生存时间。尽管目前对于免疫检查点认识有限,但免疫检查点抑制剂作为新的治疗方法有望改变乳腺癌的治疗模式。本篇综述将介绍乳腺癌中免疫检查点的研究进展。 相似文献
14.
15.
16.
Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment. 相似文献
17.
Hassan Mohammed Abushukair Anwaar Saeed 《World journal of gastrointestinal oncology》2022,14(6):1210-1212
Hepatocellular carcinoma (HCC) is one of the deadliest and most common malignancies of the liver. Considering the rich immune background of carcinogenesis in HCC, efforts have been focused on further understanding the role of the immune system in tumor suppression and promotion. The utilization of immunotherapy in HCC has led to encouraging results that has translated to longer survival and better quality of life among patients. The development of novel HCC-tailored regimens such as vaccine therapy and adoptive cellular therapy coupled with a deeper understanding of biomarkers predictive of the response to immunotherapy will lead to better treatment outcomes. 相似文献
18.
Mark A. Baxter Fearghas Middleton Hannah P. Cagney Russell D. Petty 《British journal of cancer》2021,125(8):1068
Immune checkpoint inhibitors (ICIs) have altered the treatment paradigm across a range of tumour types, including gastro-oesophageal cancers. For patients with any cancer type who respond, ICIs can confer long-term disease control and significantly improve survival and quality of life, but for patients with gastro-oesophageal cancer, ICIs can be transformative, as durable responses in advanced disease have hitherto been rare, especially in those patients who are resistant to first-line cytotoxic therapies. Results from trials in patients with advanced-stage gastro-oesophageal cancer have raised hopes that ICIs will be successful as adjuvant and neoadjuvant treatments in early-stage disease, when the majority of patients relapse after potential curative treatments, and several trials are ongoing. Unfortunately, however, ICI-responding patients appear to constitute a minority subgroup within gastro-oesophageal cancer, and resistance to ICI therapy (whether primary or acquired) is common. Understanding the biological mechanisms of ICI resistance is a current major research challenge and involves investigation of both tumour and patient-specific factors. In this review, we discuss the mechanisms underlying ICI resistance and their potential specific applications of this knowledge towards precision medicine strategies in the management of gastro-oesophageal cancers in clinical practice.Subject terms: Gastric cancer, Oesophageal cancer 相似文献
19.
Schett Anne Rothschild Sacha I. Curioni-Fontecedro Alessandra Krhenbhl Stephan Frh Martin Schmid S. Driessen Christoph Joerger Markus 《Cancer chemotherapy and pharmacology》2020,85(1):121-131
Cancer Chemotherapy and Pharmacology - In this study, we test the hypothesis that the use of ATB reduces the efficacy of PD(L)1-targeting mAb. We included patients with locally advanced, inoperable... 相似文献
20.
近年来,转移性或局部晚期非小细胞肺癌的治疗取得了较大的进展,特别是在一线治疗或治疗后出现进展的患者。通过联合治疗提高疗效已成为该领域的主要研究方向,对于没有驱动基因突变或对靶向治疗无效的患者,这种探索尤为迫切。有证据表明促血管生成因子具有免疫抑制活性,这使得研究人员开始评估抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的潜在协同作用。本文就抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的理论基础及临床研究进行综述。 相似文献